Evidence map›Paper›PMID 41273656›Full record

ReviewMethods in molecular biology (Clifton, N.J.)2026

CAR-T Cell Therapy for Central Nervous System Tumors.

Masasuke Ohno, Mitsugu Fujita

Abstract readReview
PubMed Publisher
In one paragraph

Review in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Masasuke OhnoDepartment of Neurosurgery, Aichi Cancer Center, Nagoya, Japan. m.ono@aichi-cc.jp.
Mitsugu FujitaCenter for Medical Education and Clinical Training, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chimeric antigen receptor (CAR) T cell therapy has emerged as a promising immunotherapy for central nervous system (CNS) tumors, despite the unique biological barriers posed by the blood-brain barrier (BBB) and immunosuppressive tumor microenvironment (TME). This chapter comprehensively reviews the evolution of CAR designs, gene delivery methods using lentiviral vectors (LVVs), and clinical applications for CNS tumors. We discuss current issues in CAR-T cell therapy for CNS tumors, while highlighting the strategies about new CAR designs and novel delivery methods to overcome these issues.

Indexed as

Central Nervous System NeoplasmsGenetic VectorsGene Transfer TechniquesImmunotherapy, AdoptiveReceptors, Chimeric AntigenBlood-Brain BarrierHumansImmune ToleranceLentivirusProtein DomainsTumor MicroenvironmentReceptors, Chimeric AntigenBlood–brain barrierCentral nervous system tumorsChimeric antigen receptor T cell therapyGlioblastomaLentiviral vectorsTumor microenvironment

Identifiers

PMID41273656

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.